We strongly advise you to harness Zoetis fundamental analysis to see if markets are presently mispricing the firm. Specifically this interface allows you to validate available financial indicators of Zoetis as well as the relationship between them. We found thirty-eight available indicators for Zoetis which can be compared to its rivals. To make sure the equity is not overpriced, please check out all Zoetis fundamentals including its Gross Profit, Debt to Equity and the relationship between Price to Book and Cash and Equivalents . Given that Zoetis has Price to Earning of 44.73 , we strongly advise you confirm Zoetis prevalent market performance to make sure the company can sustain itself down the road. Use Zoetis to enhance returns of your portfolios. The stock experiences large bullish trend. Check odds of Zoetis to be traded at $140.93 in 30 days.
Zoetis Company Summary
Zoetis competes with Vertex Pharmaceuticals, Dr Reddys, Perrigo Company, and Regeneron Pharmaceuticals. Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.
Zoetis Return On Asset vs Price to Earnings To Growth
Zoetis is rated fourth in return on asset category among related companies. It is rated fifth in price to earnings to growth category among related companies producing about 0.25 of Price to Earnings To Growth per Return On Asset. The ratio of Return On Asset to Price to Earnings To Growth for Zoetis is roughly 3.93
|Return On Asset ( % )|
|Price to Earnings To Growth ( times )|
Zoetis Systematic Risk
Zoetis Thematic Clasifications
Zoetis October 22, 2019 Opportunity Range
|Value At Risk||(2.33)|